Kandhasamy Sreemanjari, Lepigeon Karine, Baggio Stéphanie, Céline Roulet, Ceulemans Michael, Winterfeld Ursula, Jenkinson Stephen P, Francini Katyuska, Maisonneuve Emeline, Panchaud Alice
Instiute of Primary Health Care (BIHAM), University of Bern, Mittelstrasse 43, 3012, Bern, Switzerland.
Graduate School of Health Sciences, University of Bern, Bern, Switzerland.
BMC Pregnancy Childbirth. 2025 Apr 16;25(1):456. doi: 10.1186/s12884-024-07062-1.
Previously conducted studies have observed an increased risk of adverse maternal and neonatal outcomes with prenatal exposure to cocaine and opioids. However, these studies used drug-free reference groups which did not efficiently control for confounders associated with polysubstance use in pregnancy. Thus, we conducted an observational study to compare the risk of adverse obstetrical and neonatal outcomes in women who consumed cocaine and/or opioids during pregnancy to women who consumed only cannabis in pregnancy.
This observational study was conducted with data collected from pregnant women followed for addiction from the beginning of their pregnancy until childbirth at the perinatal consultation center Addi-Vie at CHUV Lausanne, Switzerland. Women who reported consuming cocaine, opioids, or both along with or without cannabis were included in the exposed group, while women who reported use of only cannabis during pregnancy were included in the reference group. We assessed for two adverse composite outcomes namely: adverse obstetrical composite outcome (4 outcomes) and adverse neonatal composite outcome (7 outcomes). Weighted logistic regression with weights obtained through inverse probability treatment weighting was conducted. For this analysis, we reported a conditional odds ratio (OR) and 95% confidence interval (CI).
We included 177 pregnant women in this study, with 80 included in the exposed group and 97 included in the reference group. In the exposed group, 81.2% of women reported the use of opioids, and 39.9% of women reported the use of cocaine during pregnancy. In this study, prenatal cocaine and/or opioid exposure was associated with reduced odds of adverse obstetrical composite outcomes (OR: 0.39, 95% CI: 0.17-0.88) compared to prenatal cannabis use. We also observed that the pregnant women exposed to cocaine and/or opioids during pregnancy were at 3.88 (OR: 3.88, 95% CI: 1.23-12.23) times higher odds of experiencing the adverse neonatal composite outcome compared to our reference group.
Prenatal use of cocaine and/or opioids during pregnancy is observed to increase the odds of adverse neonatal composite outcomes. Encouraging substance users to seek antenatal care in earlier stages of pregnancy and targeted treatment approaches through interprofessional collaboration could prevent such adverse outcomes in pregnancy.
先前进行的研究观察到,孕期接触可卡因和阿片类药物会增加孕产妇和新生儿不良结局的风险。然而,这些研究使用的无药物参考组未能有效控制与孕期多物质使用相关的混杂因素。因此,我们开展了一项观察性研究,以比较孕期使用可卡因和/或阿片类药物的女性与孕期仅使用大麻的女性发生不良产科和新生儿结局的风险。
这项观察性研究使用的数据来自瑞士洛桑大学医院围产期咨询中心Addi-Vie从怀孕开始直至分娩对成瘾孕妇进行随访收集的数据。报告使用可卡因、阿片类药物或两者同时使用(无论是否使用大麻)的女性被纳入暴露组,而报告孕期仅使用大麻的女性被纳入参考组。我们评估了两个不良复合结局,即:不良产科复合结局(4个结局)和不良新生儿复合结局(7个结局)。采用通过逆概率治疗加权获得权重的加权逻辑回归进行分析。对于该分析,我们报告了条件比值比(OR)和95%置信区间(CI)。
本研究纳入了177名孕妇,其中80名被纳入暴露组,97名被纳入参考组。在暴露组中,81.2%的女性报告在孕期使用阿片类药物,39.9%的女性报告在孕期使用可卡因。在本研究中,与孕期使用大麻相比,产前接触可卡因和/或阿片类药物与不良产科复合结局的几率降低相关(OR:0.39,95%CI:0.17 - 0.88)。我们还观察到,与参考组相比,孕期接触可卡因和/或阿片类药物的孕妇发生不良新生儿复合结局的几率高出3.88倍(OR:3.88,95%CI:1.23 - 12.23)。
观察到孕期使用可卡因和/或阿片类药物会增加不良新生儿复合结局的几率。鼓励药物使用者在怀孕早期寻求产前护理,并通过跨专业协作采取针对性的治疗方法,可以预防孕期此类不良结局。